RenBio’s Post

We are excited to share our latest paper Cell Press on RECOVER by Yoshua Bengio and his students P. Bertin, J. Rector-Brooks, D. Sharma and M. Korablyov. The work has been done in collaboration with J. P. Taylor-King’s team from Relation Therapeutics and Luke Lairson’s team from Scripps Research. Highlights: - The RECOVER pipeline guides cell viability assays and selects drug combinations - Increasing enrichment for synergism is achieved through five rounds of experiments - In silico benchmarking suggests a ~5–10x fold enrichment compared to random selection https://lnkd.in/gpp-2JU9

Join Rockland Immunochemicals, Inc. on June 5th from 10:00-11:00 AM EST as Peter Oliver, PhD - Head of Biology at NATA - Nucleic Acid Therapy Accelerator and Carl Ascoli, BS, MS, PhD - CSO at Rockland, discuss breakthroughs in oligonucleotide drug delivery and detection. Learn how Rockland's ModDetect anti-PS and anti-MOE Panels are advancing RNA therapeutic research, overcoming drug delivery challenges, and improving ADMET profiling. 👉 Key Insights: - Application of ModDetect panels in RNA therapeutics - Challenges in efficient endosomal escape - Importance of rigorous testing for safety and efficacy - Opportunities for future research collaboration Don't miss out on expert insights into the future of nucleic acid therapies! #Webinar #Biotech #Oligonucleotide #RNAtherapeutics #DrugDelivery

Register to learn more about NATA - Nucleic Acid Therapy Accelerator's use of Rockland Immunochemicals, Inc. reagents to understand more about the intracellular uptake and localization of therapeutic oligonucleotides.

Thanks to the surface plasmon resonance (SPR), translational scientists can evaluate antibody-antigen and antibody-FCγ-receptor interactions, as this technique offers valuable information on the potential of an antibody candidate to become a safe, stable, and effective drug. Learn more about SPR and how they use this to help them in selecting the most promising lead candidates from the plethora of biotherapeutic antibodies generated during development in this new white paper from Cytiva. Download the white paper here: https://lnkd.in/gz3wMDWq

Evitria’s journal club - paper of the week no. 2 Fc galactosylation follows consecutive reaction kinetics and enhances immunoglobulin G hexamerization for complement activation (March 2021) from Bingchuan Wei et al. Antibody glycan structures are gaining more and more interest for their therapeutic impact. Here the team at Genentech developed a kinetic model of the galactose transfer reaction, and with it discovered the molecular basis for Fc glycan terminal galactosylation changing the three-dimensional conformation of the Fc domain. This in turn facilitates the IgG1 hexamerization, and so enhances C1q avidity and subsequent complement activation – small changes have a big impact! Access the paper and learn more about how our team can support your antibody engineering work here:  https://lnkd.in/eqZVu3Fp #antibodies #glycans #antibodyengineering

📢 Final days at #PEGSEurope! Time to Save the Date again - tomorrow November 16, at 16:20 CET. 👉 Join us for another insightful presentation, this time featuring Mattias Levin, PhD, Director, Antibody Technology Innovation at Alligator Bioscience AB. Discover the innovative #ATOR4066, a novel bispecific antibody in the RUBY format, targeting the tumor-associated antigen CEA (CEACAM5) on tumor cells and CD40 on myeloid cells. Mattias will delve into the data-driven design of #ATOR4066, showcasing its potential to induce efficient CEA conditional activation of myeloid cells and drive uptake of neoantigen-containing tumor-derived material, leading to cross-priming of tumor-specific T cells. 🔬 Presentation: "Design and Engineering of ATOR-4066 Using the RUBY Format: A Novel Neo-X-Prime bsab Targeting CD40 and CEA" 📍 Location: PEGS 15th Annual Protein and Engineering Symposium 📅 Date: November 16 🕰 Time: 16:20 CET 🌐 Venue: Lisbon Congress Center, Lisbon, Portugal

🚀Upcoming Webinar: Accelerating Oligonucleotide-based Therapies - Advancements in Detection and Localization  Join us for a live webinar featuring Peter Oliver, our Head of Biology, alongside Carl Ascoli, BS, MS, PhD, Chief Science Officer at Rockland Immunochemicals, Inc., to explore advanced techniques in oligonucleotide drug delivery and detection. 📅 Date: 5 June 2024 🕒 Time: 10:00-11:00 am EST; 15:00-16:00 BST Pete and Carl will discuss how Rockland's ModDetect anti-PS and anti-MOE Panels are enhancing the precise detection of RNA therapeutic modalities, including antisense oligonucleotides (ASOs) and siRNA, offering significant improvements in the elucidation of ADMET profiles of potential therapeutics. Key topics include: ◾ Practical applications of Rockland's ModDetect anti-PS and MOE antibody panels in RNA therapeutic research  ◾ Challenges in drug delivery systems, particularly in achieving efficient endosomal escape  ◾ The role of rigorous in vitro and in vivo testing in validating the safety and efficacy of oligonucleotide therapeutics ◾ Opportunities for future collaboration in advancing nucleic acid therapeutic research  Don't miss the opportunity to hear their insights! 🔗 https://lnkd.in/gfwxp6Ea #NATA #Research #Science #Innovation #AdvancedTherapies #therapeutics #drugdiscovery #NucleicAcidTherapy #NATs #NucleicAcidTherapeutics #oligotherapies #oligonucleotides #therapeutics #drugdiscovery #biotech #biotechnology #Biomedical

Resmetirom (Rezdiffra®) is the first FDA-approved drug for the management of MASH. At Gubra, we have established highly robust and reproducible therapeutic outcomes of Resmetirom intervention treatment in the translational, biopsy-confirmed GAN DIO-MASH mouse model. The GAN DIO-MASH mouse is Gubra's flagship model readily applicable for efficacy profiling of preclinical drug candidates. Download the poster and learn more about Resmetirom's effects on clinically relevant metabolic, biochemical and histological endpoints in the model. #MASH #NASH #TranslationalModel #ClinicalTranslatability #Resmetirom #Rezdiffra

🎯#ADCs have traditionally focused on "celebrity" targets. However, while still slow, the trend is shifting towards novel targets, promising broader therapeutic applications. Advancements in antibody engineering are pivotal to this shift. In a recent Q&A with Doug Chapnick, Founder & CEO of BioLoomics, Rebecca Bair and I discussed these developments as well as exciting company updates! Our full interview with BioLoomics drops tomorrow. Stay tuned!!🔥 If you are interested in learning more about DeciBio's ADC tracker, TheraTrack, do not hesitate to reach out! We track all ADCs in development as well as their characteristics!! #biotechnews #precisionmedicine